# Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors

> **NCT04096638** · PHASE1 · COMPLETED · sponsor: **invoX Pharma Limited** · enrollment: 61 (actual)

## Conditions studied

- Melanoma
- Head and Neck Squamous Cell Carcinoma
- Solid Tumor

## Interventions

- **DRUG:** SB 11285
- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT04096638
- **Lead sponsor:** invoX Pharma Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-23
- **Primary completion:** 2024-07-16
- **Final completion:** 2024-07-16
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2024-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04096638

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04096638, "Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04096638. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*